Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · United Therapeutics (UTHR)

United Therapeutics authorizes new $2.0 billion share repurchase program through October 2027

Neutral Impact 4 of 5 shareholder

United Therapeutics' Board approved a share repurchase program of up to $2.0 billion of common stock on October 21, 2026, effective for one year through October 21, 2027. The company says the authorization gives it capacity to buy back shares, though it is not obligated to use it.

Key points

  • Authorization covers up to $2.0 billion of common stock, running through October 21, 2027.
  • Repurchases may be made through accelerated share repurchases, open market or privately negotiated transactions, or other means, and may start or stop at any time.
  • An existing accelerated share repurchase entered in September 2026 under the prior authorization has a scheduled termination in the fourth quarter of 2026 and will not reduce the new authorization.

The filing

CompanyUnited Therapeutics (UTHR)
Form8-K, current report
Filed with the SECOct 22, 2026, 7:00 AM ET
Accession number0001104659-26-117964

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.